O R I G I N a L I N V E S T I G a T I O N Open Access the Role of Profilin-1 in Endothelial Cell Injury Induced by Advanced Glycation End Products (ages)

Background: Accumulation of advanced glycation end products (AGEs) in the vasculature triggers a series of morphological and functional changes contributing to endothelial hyperpermeability. The reorganisation and redistribution of the cytoskeleton regulated by profilin-1 mediates endothelial cell contraction, which results in vascular hyperpermeability. This study aimed to investigate the pivotal role of profilin-1 in the process of endothelial cell damage induced by AGEs. Methods: Human umbilical vein endothelial cells (HUVECs) were incubated with AGEs. The mRNA and protein expression of profilin-1 was determined using real-time PCR and western blotting analyses. The levels of intercellular adhesion molecule-1 (ICAM-1), nitric oxide (NO) and reactive oxygen species (ROS), as well as the activities of nuclear factor-κB (NF-κB) and protein kinase C (PKC), were detected using the appropriate kits. The levels of asymmetric dimethylarginine (ADMA) were determined using HPLC. The distribution of the cytoskeleton was visualised using immunofluorescent staining. Results: Compared with the control, incubation of endothelial cells with AGEs (200 μg/ml) for 4 or 24 h significantly up-regulated the mRNA and protein expression of profilin-1, markedly increased the levels of ICAM-1 and ADMA and decreased the production of NO (P<0.05, P<0.01), which was significantly attenuated by pretreatment with DPI (an antioxidant), GF 109203X (PKC inhibitor) or BAY-117082 (NF-κB inhibitor). DPI (10 μmol/L) markedly decreased the elevated levels of ROS induced by AGEs (200 μg/ml, 24 h); however, GF 109203X (10 μmol/L) and BAY-117082 (5 μmol/L) exhibited no significant effect on the formation of ROS by AGEs. Immunofluorescent staining indicated that AGEs markedly increased the expression of profilin-1 in the cytoplasm and the formation of actin stress fibres, resulting in the rearrangement and redistribution of the cytoskeleton. Disruption of profilin-1 gene expression attenuated the extent of endothelial abnormalities by reducing ICAM-1 and ADMA levels and elevating NO levels (P<0.05, P<0.01), but this disruption had no effect on the activities of NF-κB and PKC (P>0.05).

[1]  S. Shoelson,et al.  Profilin-1 Haploinsufficiency Protects Against Obesity-Associated Glucose Intolerance and Preserves Adipose Tissue Immune Homeostasis , 2013, Diabetes.

[2]  M. Yokoro,et al.  Involvement of advanced glycation end product-induced asymmetric dimethylarginine generation in endothelial dysfunction , 2013, Diabetes & vascular disease research.

[3]  A. Ceriello The emerging challenge in diabetes: the "metabolic memory". , 2012, Vascular pharmacology.

[4]  Hong Li,et al.  Advanced glycation end products impair the migration, adhesion and secretion potentials of late endothelial progenitor cells , 2012, Cardiovascular Diabetology.

[5]  Hongxia Liu,et al.  RhoA/ROCK-dependent moesin phosphorylation regulates AGE-induced endothelial cellular response , 2012, Cardiovascular Diabetology.

[6]  M. Odenthal,et al.  Profilin-1 Is Expressed in Human Atherosclerotic Plaques and Induces Atherogenic Effects on Vascular Smooth Muscle Cells , 2010, PloS one.

[7]  P. Home,et al.  The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease , 2010, Current cardiology reviews.

[8]  Merlin C. Thomas,et al.  Advanced glycation end-products induce vascular dysfunction via resistance to nitric oxide and suppression of endothelial nitric oxide synthase , 2010, Journal of hypertension.

[9]  A. Hirose,et al.  Advanced glycation end products increase endothelial permeability through the RAGE/Rho signaling pathway , 2010, FEBS letters.

[10]  M. Ihnat,et al.  Clinical review 2: The "metabolic memory": is more than just tight glucose control necessary to prevent diabetic complications? , 2009, The Journal of clinical endocrinology and metabolism.

[11]  Li-jun Wang,et al.  Taurine rescues vascular endothelial dysfunction in streptozocin-induced diabetic rats: correlated with downregulation of LOX-1 and ICAM-1 expression on aortas. , 2008, European journal of pharmacology.

[12]  S. Yamagishi,et al.  Role of asymmetric dimethylarginine (ADMA) in diabetic vascular complications. , 2008, Current pharmaceutical design.

[13]  Z. Guo,et al.  Advanced oxidation protein products activate vascular endothelial cells via a RAGE-mediated signaling pathway. , 2008, Antioxidants & redox signaling.

[14]  A. Kazlauskas,et al.  Oxysterol and Diabetes Activate STAT3 and Control Endothelial Expression of Profilin-1 via OSBP1* , 2008, Journal of Biological Chemistry.

[15]  A. Malik,et al.  Regulation of Endothelial Junctional Permeability , 2008, Annals of the New York Academy of Sciences.

[16]  H. Makino,et al.  Regulation of Src homology 2-containing protein tyrosine phosphatase by advanced glycation end products: the role on atherosclerosis in diabetes. , 2007, Metabolism: clinical and experimental.

[17]  A. Kazlauskas,et al.  Attenuated Expression of Profilin-1 Confers Protection From Atherosclerosis in the LDL Receptor–Null Mouse , 2007, Circulation research.

[18]  Bernd Stratmann,et al.  Effects of low- and high-advanced glycation endproduct meals on macro- and microvascular endothelial function and oxidative stress in patients with type 2 diabetes mellitus. , 2007, The American journal of clinical nutrition.

[19]  P. Roy,et al.  Silencing profilin-1 inhibits endothelial cell proliferation, migration and cord morphogenesis , 2006, Journal of Cell Science.

[20]  Mingde Zhao,et al.  Advanced glycation end products induce actin rearrangement and subsequent hyperpermeability in endothelial cells , 2006 .

[21]  M. Morales,et al.  Advanced glycation and endothelial functions: a link towards vascular complications in diabetes. , 2004, Life sciences.

[22]  R. de Caterina,et al.  Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. , 2004, Cardiovascular research.

[23]  J. Mamputu,et al.  Signalling pathways involved in retinal endothelial cell proliferation induced by advanced glycation end products: inhibitory effect of gliclazide , 2004, Diabetes, obesity & metabolism.

[24]  H. Parving,et al.  Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. , 2004, Diabetes care.

[25]  N. Savion,et al.  Flow Conditions Modulate Homocysteine Induced Changes in the Expression of Endothelial Cell Genes Associated with Cell-Cell Interaction and Cytoskeletal Rearrangement , 2002, Thrombosis and Haemostasis.

[26]  Timothy S Kern,et al.  Activation of nuclear factor-kappaB induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes. , 2002, Diabetes.

[27]  K. Otero,et al.  Albumin-derived advanced glycation end-products trigger the disruption of the vascular endothelial cadherin complex in cultured human and murine endothelial cells. , 2001, The Biochemical journal.

[28]  G. King,et al.  The role of oxidative stress in the onset and progression of diabetes and its complications: asummary of a Congress Series sponsored byUNESCO‐MCBN, the American Diabetes Association and the German Diabetes Society , 2001, Diabetes/metabolism research and reviews.

[29]  J. Nejima,et al.  Increased serum concentrations of advanced glycation end products: a marker of coronary artery disease activity in type 2 diabetic patients , 2001, Heart.

[30]  Y. Kaneda,et al.  Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage , 2000, Nature.

[31]  R. H. Sohn,et al.  Regulation of endothelial cell adhesion by profilin , 1997, Current Biology.

[32]  G. Santulli,et al.  Cardiovascular Diabetology , 2023 .

[33]  S. Yamagishi,et al.  Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression. , 2013, The American journal of pathology.

[34]  W. Zhan The Morphological Changes of Vascular Endothelial Cadherin in Human Umbilical Vein Endothelial Cells Induced by Advanced Glycation End Products , 2008 .

[35]  A. Verin,et al.  Molecular Mechanisms of Thrombin-Induced Endothelial Cell Permeability , 2004, Biochemistry (Moscow).